In patients with advanced gastrointestinal stromal tumors (GIST) that progressed on or were intolerant to imatinib, the efficacy of ripretinib was comparable to sunitinib. These findings from the INTRIGUE trial were presented during the January session of the American Society of Clinical Oncology (ASCO) Plenary Series.
January 24, 2022
January 18, 2022
Results from the randomized international phase III TOPAZ-1 trial showed that the checkpoint immunotherapy durvalumab (Imfinzi) plus chemotherapy drugs gemcitabine and cisplatin significantly improved overall survival in patients with advanced biliary tract cancer compared to patients who received a placebo plus the chemotherapy drugs. Biliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.
January 18, 2022
Results from the randomized international phase III HIMALAYA trial showed that a combination of durvalumab (Imfinzi) plus the experimental drug tremelimumab, both immunotherapies, significantly improved overall survival in patients with advanced, unresectable hepatocellular carcinoma, the most common type of liver cancer, compared to patients who received only sorafenib (Nexavar).
December 23, 2021
Findings on combination therapies with immunotherapy drugs for patients with biliary tract cancer and hepatocellular carcinoma will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 650 abstracts that will be presented at the Symposium.
November 15, 2021
Two studies from the inaugural ASCO Plenary Series session will highlight the latest practice-changing results in advanced melanoma and digital symptom monitoring. The studies will be presented in a live broadcast session on November 16, 2021, at 3:00 PM ET.
September 20, 2021
Interventions that paired community-based health workers with low-income and minority patients with cancer improved quality of life and may be a more effective and sustainable way to ensure equitable cancer care, according to a study to be presented as part of the 2021 ASCO Quality Care Symposium.
September 20, 2021
Ten noteworthy studies from the 2021 Quality Care Symposium explore topics such as financial burden of cancer treatment, fertility preservation, hidden disparities in breast cancer, and more. Leading cancer experts are available to comment on the on-demand and scheduled broadcast content from the 2021 Quality Care Symposium.
September 20, 2021
The majority (72.3%) of oral anticancer drugs received by patients required prior authorization, which was found to be associated with delayed time to drug receipt, according to a study to be presented at the 2021 ASCO Quality Care Symposium.
August 17, 2021
Research covering cancer treatment delays due to insurance type, and improvements in cancer care and quality of life for low-income and minority patients seen with integrated community-based interventions will be highlighted in the 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium’s official Press Program. Studies featured in the Press Program are among the more than 300 abstracts that will be presented at the Symposium.
June 3, 2021
Compared to standard of care chemotherapy, both a dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced esophageal squamous cell carcinoma (ESCC), particularly those positive for the immune checkpoint protein PD-L1, according to data from a phase III trial to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 3, 2021
Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type of kidney cancer, clear-cell renal carcinoma (RCC). A phase III international study, to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, found that pembrolizumab (Keytruda) could offer an effective treatment for patients currently with few other options. KEYNOTE-564 is the first phase III study with a checkpoint inhibitor in the adjuvant setting to improve DFS for patients with high risk fully resected RCC.
June 3, 2021
The addition of 1 year of the PARP inhibitor olaparib after completion of standard neoadjuvant or adjuvant chemotherapy, surgery and any radiation therapy needed, significantly improved invasive disease-free (IDFS) and distant disease-free survival (DDFS) in patients with BRCA1/2 germline mutations and high-risk early-stage breast cancer that is negative for human epidermal growth factor receptor 2-(HER2), according to new research to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 3, 2021
Additional chemotherapy given after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and is associated with additional side effects, according to results of a phase III international trial.
June 3, 2021
The addition of the immunotherapy agent toripalimab to standard first-line chemotherapy significantly delayed disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to new research. The phase III international study, to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, may represent a paradigm shift in the care of these patients, for whom there are currently few treatment options
June 3, 2021
The investigational therapy 177Lu-PSMA-617 significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) when added to standard of care treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with standard of care alone, according to new research.
Pages |